Natalie E. Simpson

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma”.

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0618

N/A

0DataRank · unranked

56 citations

Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li +8 more

Data from High Levels of Hsp90 Cochaperone p23 Promote Tumor Progression and Poor Prognosis in Breast Cancer by Increasing Lymph Node Metastases and Drug Resistance

(2023)10.1158/0008-5472.c.6500681

N/A

0DataRank · unranked

0 citations

W. Marcus Lambert, Renecia A. Watkins, Shah Giashuddin, S. Joseph Huang, Ellinor Oxelmark +9 more

Data from High Levels of Hsp90 Cochaperone p23 Promote Tumor Progression and Poor Prognosis in Breast Cancer by Increasing Lymph Node Metastases and Drug Resistance

(2023)10.1158/0008-5472.c.6500681.v1

N/A

0DataRank · unranked

0 citations

W. Marcus Lambert, Renecia A. Watkins, Shah Giashuddin, S. Joseph Huang, Ellinor Oxelmark +9 more